Progesterone Receptor Negative Completed Phase 1 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01145430Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerTreatment